Smith v. Medtronic, Inc.

CourtDistrict Court, N.D. California
DecidedJuly 28, 2023
Docket4:22-cv-09179
StatusUnknown

This text of Smith v. Medtronic, Inc. (Smith v. Medtronic, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Smith v. Medtronic, Inc., (N.D. Cal. 2023).

Opinion

1 2 3 4 5 6 7 UNITED STATES DISTRICT COURT 8 NORTHERN DISTRICT OF CALIFORNIA 9 10 MIA INEZ SMITH, individually and as Case No. 22-cv-09179-JSW successor-in-interest to MICHAEL RAY 11 SMITH, deceased; and MAKIA RAQUEL SMITH, individually, and successor-in- ORDER DENYING MOTION TO 12 interest to MICHAEL RAY SMITH, DISMISS deceased, Re: Dkt. No. 15 13 Plaintiffs, 14 v.

15 MEDTRONIC, INC.; MEDTRONIC USA, 16 INC.; COVIDIEN LP; COVIDIEN SALES LLC; and DOES 1 to 50, 17 Defendants. 18

19 Now before the Court is the motion to dismiss the first amended complaint filed by 20 Defendants Medtronic, Inc., Medtronic USA, Inc., Covidien LP, and Covidien Sales LLC 21 (collectively, “Defendants”). The Court has considered the parties’ papers, relevant legal 22 authority, and the record in this case. For the reasons that follow, the Court DENIES Defendants’ 23 motion to dismiss. 24 BACKGROUND 25 Mia Inez Smith and Maki Raquel Smith (“Plaintiffs”), daughters of Michael Ray Smith, 26 Deceased (“Decedent”) initiated this action by filing a complaint in the Superior Court of 27 1 removed this action on December 30, 2022. (Dkt. No. 1.) Thereafter, on January 20, 2023, 2 Plaintiffs filed their first amended complaint (“FAC”). (Dkt. No. 13.) On February 10, 2023, 3 Defendants moved to dismiss pursuant to Federal Rules of Civil Procedure 8(a)(2) and 12(b)(6) 4 for failure to state a claim upon which relief can be granted.1 5 According to the amended complaint, on March 7, 2022, Decedent underwent video- 6 assisted thoracoscopic surgery at Highland Hospital in Oakland, California, during which the 7 operating surgeon used a l-hook ligature device (the “Device”). (Id. ¶¶ 1, 2.) During the surgery, 8 which was converted to an open left thoracotomy, repair of cardiac injury, and resection of 9 mediastinal mass, the Device “suddenly and unexpectedly broke, cracked, fractured and/or 10 otherwise failed.” (Id. ¶ 2.) This caused an avulsion injury to Decedent’s left anterior descending 11 artery and caused bleeding, injury, and other damage. (Id.) The surgery was “complicated by [the 12 Device’s] fracture interoperatively and [caused] 2L intraoperative blood loss with injury to left 13 anterior descending branch requiring ligation and subsequent respiratory acidosis, shock, [and] 14 AKI with hyperkalemia.” (Id. ¶ 21.) 15 Plaintiffs further allege that the Device was only cleared for sale under Section 510(k) of 16 the Medical Device Act Amendments (“MDA”), based on an abbreviated process for securing 17 clearance from the United States Food and Drug Administration (“FDA”). (Id. ¶¶ 13-16.) 18 Plaintiffs contend that the abbreviated process “allows manufacturers to secure FDA clearance by 19 merely showing that a device is ‘substantially equivalent’ to a device already on the market, i.e., a 20 ‘predicate device’ which literally may not ever have gone through any significant FDA 21 evaluation/analysis.” (Id. ¶ 15.) Plaintiffs allege that Defendants submitted the Device for Section 22 510(k) pre-market clearance on June 30, 2016, and on September 16, 2016, the FDA issued a 23 clearance letter for the Device “based on a substantial equivalence to legally marketed predicate 24 devices marketed in interstate commerce prior to May 28, 1976, not efficacy or safety.” (Id. ¶¶ 13, 25 16.) Plaintiffs allege that the FDA expressly included in its clearance letter for the Device that 26 “‘FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a 27 1 determination that your device complies with other requirements of the [MDA] or any Federal 2 statutes and regulations administrated by other Federal agencies.” (Id. ¶ 16.) 3 Plaintiffs assert that a “health professional company representative of Defendants was 4 present” during Decedent’s surgery on March 7, 2022. (Id. ¶ 17.) Plaintiff further contend that 5 the representative reported to the FDA on July 1, 2022, that during the surgery, the Device “split 6 from the handle half way down the outside sleeve.” (Id. ¶ 18.) Plaintiffs allege that during the 7 surgery, the Device “broke with a sharp edge at the fracture site noted during removal” and 8 “fractured intraoperatively causing injury to [Decedent]’s left anterior descending artery.” (Id. ¶¶ 9 19, 20.) 10 As a result of the Device breaking unexpectedly, Plaintiffs allege that Decedent suffered 11 “conscious pain and suffering for the remainder of his life, and ultimately died as a result of his 12 injuries on March 19, 2022.” (Id. ¶¶ 3, 23.) Following the death of their father, as successors in 13 interest, Plaintiffs filed suit for (1) strict products liability – manufacturing defect and failure to 14 warn and (2) negligent products liability – (A) negligent design, manufacturing, and sale; (B) 15 failure to recall/retrofit; and (C) failure to warn. Defendants move to dismiss on the basis that the 16 first amended complaint fails to state well-pleaded facts giving rise to a plausible claim for relief. 17 ANALYSIS 18 A. Applicable Legal Standards. 19 A motion to dismiss is proper under Rule 12(b)(6) where the pleadings fail to state a claim 20 upon which relief can be granted. A court’s “inquiry is limited to the allegations in the complaint, 21 which are accepted as true and construed in the light most favorable to the plaintiff.” Lazy Y 22 Ranch Ltd. v. Behrens, 546 F.3d 580, 588 (9th Cir. 2008). Even under the liberal pleading 23 standard of Rule 8(a)(2), “a plaintiff’s obligation to provide the ‘grounds’ of his ‘entitle[ment] to 24 relief’ requires more than labels and conclusions, and a formulaic recitation of the elements of a 25 cause of action will not do.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007) (citing 26 Papasan v. Allain, 478 U.S. 265, 286 (1986)). 27 Pursuant to Twombly, a plaintiff cannot merely allege conduct that is conceivable but must 1 claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw 2 the reasonable inference that the defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 3 556 U.S. 662, 678 (2009) (citing Twombly, 550 U.S. at 556). “The plausibility standard is not 4 akin to a ‘probability requirement,’ but it asks for more than a sheer possibility that a defendant 5 has acted unlawfully.” Id. (quoting Twombly, 550 U.S. at 556). 6 If the allegations are insufficient to state a claim, a court should grant leave to amend 7 unless amendment would be futile. See, e.g., Reddy v. Litton Indus., Inc., 912 F.2d 291, 296 (9th 8 Cir. 1990); Cook, Perkiss & Liehe, Inc. v. Northern Cal. Collection Serv. Inc., 911 F.2d 242, 246- 9 47 (9th Cir. 1990). 10 B. Strict Products Liability Claim – Manufacturing Defect. 11 A plaintiff may seek recovery for products liability based on either a theory of strict 12 liability or a theory of negligence. Under both theories, plaintiff must ultimately prove that the 13 defect caused the injury. Trejo v. Johnson & Johnson, 13 Cal. App. 5th 110, 117 (2017). Claims 14 premised on strict liability theory, unlike claims premised on negligence, do not require plaintiff to 15 prove that the defendant was negligent in causing the injury. Brown v. Superior Court, 44 Cal. 3d 16 1049, 1056 (1988). Rather, the burden of proof is eased under a under strict liability theory. Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Papasan v. Allain
478 U.S. 265 (Supreme Court, 1986)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Barker v. Lull Engineering Co.
573 P.2d 443 (California Supreme Court, 1978)
Anderson v. Owens-Corning Fiberglas Corp.
810 P.2d 549 (California Supreme Court, 1991)
Soule v. General Motors Corp.
882 P.2d 298 (California Supreme Court, 1994)
Lazy Y Ranch Ltd. v. Behrens
546 F.3d 580 (Ninth Circuit, 2008)
In Re Martin
744 P.2d 374 (California Supreme Court, 1987)
In Re Coordinated Latex Glove Litigation
121 Cal. Rptr. 2d 301 (California Court of Appeal, 2002)
Webb v. Special Electric Co., Inc.
370 P.3d 1022 (California Supreme Court, 2016)
Trejo v. Johnson
220 Cal. Rptr. 3d 127 (California Court of Appeals, 5th District, 2017)
Reddy v. Litton Industries, Inc.
912 F.2d 291 (Ninth Circuit, 1990)

Cite This Page — Counsel Stack

Bluebook (online)
Smith v. Medtronic, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/smith-v-medtronic-inc-cand-2023.